Evidence map›Paper›PMID 33921457›Full record

ReviewBiomolecules2021

A New Era of Neuro-Oncology Research Pioneered by Multi-Omics Analysis and Machine Learning.

Satoshi Takahashi, Masamichi Takahashi, Shota Tanaka, Shunsaku Takayanagi, Hirokazu Takami, Erika Yamazawa, Shohei Nambu, Mototaka Miyake, Kaishi Satomi, Koichi Ichimura and 2 more

Registry-linked trialAbstract readReview
In one paragraph

Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07243470 (A Multicenter, Open-label Phase I/II Trial Aiming to Assess the Safety and Clinical Activity of Tarlatamab in Combination With Metronomic Temozolomide in Adolescents and Adults' Patients With High Grade Brain Tumors), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07243470 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation

A Multicenter, Open-label Phase I/II Trial Aiming to Assess the Safety and Clinical Activity of Tarlatamab in Combination With Metronomic Temozolomide in Adolescents and Adults' Patients With High Grade Brain Tumors

TypeinterventionalSponsorCentre Leon BerardRan2025 to 2030Enrolled70ConditionsGlioma, CNS Tumor, Adult, CNS Tumor, ChildhoodArmsTarlatamab, Temozolomide (TMZ)
3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Satoshi TakahashiDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Masamichi TakahashiDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.ORCID 0000-0001-8792-1993
Shota TanakaDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Shunsaku TakayanagiDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Hirokazu TakamiDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.ORCID 0000-0001-9742-7462
Erika YamazawaDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Shohei NambuDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Mototaka MiyakeDepartment of Diagnostic Radiology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Kaishi SatomiDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Koichi IchimuraDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Yoshitaka NaritaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Ryuji HamamotoDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo 104-0045, Japan.

Funding

Japan Science and Technology Agency JPMJCR1689Japan Science and Technology Agency JPMJCR18Y4Japan Society for the Promotion of Science 20K17982Japan Society for the Promotion of Science JP18H04908
6 · The paper itself

Abstract

Although the incidence of central nervous system (CNS) cancers is not high, it significantly reduces a patient's quality of life and results in high mortality rates. A low incidence also means a low number of cases, which in turn means a low amount of information. To compensate, researchers have tried to increase the amount of information available from a single test using high-throughput technologies. This approach, referred to as single-omics analysis, has only been partially successful as one type of data may not be able to appropriately describe all the characteristics of a tumor. It is presently unclear what type of data can describe a particular clinical situation. One way to solve this problem is to use multi-omics data. When using many types of data, a selected data type or a combination of them may effectively resolve a clinical question. Hence, we conducted a comprehensive survey of papers in the field of neuro-oncology that used multi-omics data for analysis and found that most of the papers utilized machine learning techniques. This fact shows that it is useful to utilize machine learning techniques in multi-omics analysis. In this review, we discuss the current status of multi-omics analysis in the field of neuro-oncology and the importance of using machine learning techniques.

Indexed as

Machine LearningAnimalsBiomarkers, TumorCentral Nervous System NeoplasmsComputational BiologyGene Expression Regulation, NeoplasticHumansBiomarkers, Tumorgliomamachine learningmulti-omics analysisneuro-oncology

Identifiers

PMID33921457
PMCPMC8070530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.